SAB Biotherapeutics, Inc. (SABS) vs Vanda Pharmaceuticals Inc. (VNDA)
A side-by-side comparison of SAB Biotherapeutics, Inc. and Vanda Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
SABS
SAB Biotherapeutics, Inc.
$2.93HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
VNDA
Vanda Pharmaceuticals Inc.
$4.52HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
Total return — SABS vs VNDA
growth of $100 · dividends reinvested · last 6ySABS -96.9% (-44.1%/yr)VNDA -70.5% (-18.4%/yr)VNDA compounded faster over this window
Log scale — wide-divergence pair
SABS VNDA
SABS vs VNDA: by the numbers
- •VNDA is the larger company ($272M vs $267M market cap).
- •Both run net losses; SABS's is the smaller (0.00% vs -127.41% net margin).
Metrics side by side
Valuation
| Metric | SABS | VNDA |
|---|---|---|
| P/S ratio | N/A | 1.26 |
| P/B ratio | 1.24 | 1.23 |
Profitability
| Metric | SABS | VNDA |
|---|---|---|
| Gross margin | 0.00% | 92.82% |
| Operating margin | 0.00% | -69.95% |
| Net margin | 0.00% | -127.41% |
| ROE | -5.95% | -124.83% |
| ROIC | -31.62% | -74.73% |
Growth (annualized)
| Metric | SABS | VNDA |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -3.56% |
| EPS CAGR (5Y) | -50.57% | N/A |
| Total return CAGR (5Y) | -50.16% | -23.91% |
Frequently asked
- How have SABS and VNDA total returns compared?
- Over the past 5 years, SABS delivered -50.16% and VNDA delivered -23.91% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.